CTLA4 and cancer: Instead of eliciting a target-antigen-directed immune response in the context of a cancer vaccine, the pharmacologic interference with inhibitory immune checkpoints such as CTLA-4 or the PD-1/PD-L1 axis restored cytotoxicity of preexisting, exhausted cancer-specific T cells.